Discovery of Potent and Orally Active p53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical Development - Wikidata - awgldk - TriplyDB

Discovery of Potent and Orally Active p53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical Development

Discovery of Potent and Orally Active p53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical Development

http://www.wikidata.org/entity/Q27684218

about

Chemical Variations on the p53 Reactivation Theme Energetic Landscape of MDM2-p53 Interactions by Computational Mutagenesis of the MDM2-p53 Interaction Discovery of 4-((3'R,4'S,5'R)-6″-Chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-2″-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3″-indoline]-5'-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Nutlin-3 treatment spares cisplatin-induced inhibition of bone healing while maintaining osteosarcoma toxicity.MDM2 oligomers: antagonizers of the guardian of the genome.Chronic inflammation and cancer: potential chemoprevention through nuclear factor kappa B and p53 mutual antagonism Homozygous mdm2 SNP309 cancer cells with compromised transcriptional elongation at p53 target genes are sensitive to induction of p53-independent cell death.Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.Ubiquitin-specific proteases as therapeutic targets for the treatment of breast cancer Selective and potent proteomimetic inhibitors of intracellular protein-protein interactions Small-molecule MDM2-p53 inhibitors: recent advances.How To Design a Successful p53-MDM2/X Interaction Inhibitor: A Thorough Overview Based on Crystal Structures.Targeting RING domains of Mdm2-MdmX E3 complex activates apoptotic arm of the p53 pathway in leukemia/lymphoma cells Identification of lineariifolianoid A as a novel dual NFAT1 and MDM2 inhibitor for human cancer therapy Role of E3 ubiquitin ligases in insulin resistance.Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.Discovery of Novel 3,3-Disubstituted Piperidines as Orally Bioavailable, Potent, and Efficacious HDM2-p53 Inhibitors.Reviving the guardian of the genome: Small molecule activators of p53.Indolo-pyrido-isoquinolin based alkaloid inhibits growth, invasion and migration of breast cancer cells via activation of p53-miR34a axis.Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma.An Intriguing Correlation Based on the Superimposition of Residue Pairs with Inhibitors that Target Protein-Protein Interfaces.Design of chemically stable, potent, and efficacious MDM2 inhibitors that exploit the retro-mannich ring-opening-cyclization reaction mechanism in spiro-oxindoles.Selective and Potent Proteomimetic Inhibitors of Intracellular Protein-Protein Interactions.Antitumor evaluation and 3D-QSAR studies of a new series of the spiropyrroloquinoline isoindolinone/aza-isoindolinone derivatives by comparative molecular field analysis (CoMFA).

P2860

Q26749008-4DFA1619-8A0F-4535-887C-001574DCEE5D Q28550874-BCB793E9-8580-4443-AB82-25999B44A356 Q33572704-13315506-B7B0-4B2E-8847-C877D616FE0F Q33918015-69544521-F503-49F7-9A2B-C4A130A02D93 Q33922100-C78C8B43-BD69-41F7-A1E5-63E94A322BF8 Q34079481-3772A4ED-C05F-41FD-AA03-C08D7B239B87 Q34496093-2BED6CDF-7765-4DAA-A368-2E08AE55FA5F Q35087851-D841B417-C671-4FF3-AC20-1EADA69D9558 Q35258016-5F562803-8986-41F4-943A-B756BDF4DD63 Q35555133-E5D9F7A0-4EC3-4B20-8FDD-2E0460A6C95B Q35617077-E5320F2D-5143-4B68-8072-11F1F3BA37E4 Q35871210-60A32EED-C3FC-495C-9244-116FC138B990 Q36485161-F644F9D4-5BC6-442A-8C63-9F77435E9B6F Q37097416-239813C9-91E8-485D-90FD-0F7135912B51 Q38813011-85330A4E-DFC6-42FE-B4F0-01B54E7C6B91 Q38865504-A4CA78AE-0DD0-40C9-992A-2F08432208F1 Q38966129-04ECA166-EA23-4F93-A3A3-41C42C56B868 Q39205536-DB03D040-1356-4011-A675-036C9AF624E8 Q39711305-058F2D07-2F26-4960-BE2B-E23CD40EF3DA Q41343291-BDD18764-4234-4C63-B748-798D54136AF7 Q41357989-12C0B036-916A-458D-871B-2704EEDCAE90 Q42099865-4BA2679A-4480-49BE-8568-51F569538345 Q42544825-D2CFC468-32A3-410A-B902-94DEA31C402F Q48184446-E04ECF18-4DAC-42A8-A2D7-87A90888B738

P2860

Discovery of Potent and Orally Active p53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical Development

http://www.wikidata.org/entity/Q27684218

description

2014 nî lūn-bûn

@nan

2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

name

Discovery of Potent and Orally ...... Potential Clinical Development

@ast

Discovery of Potent and Orally ...... Potential Clinical Development

@en

Discovery of Potent and Orally ...... Potential Clinical Development

@nl

type

label

Discovery of Potent and Orally ...... Potential Clinical Development

@ast

Discovery of Potent and Orally ...... Potential Clinical Development

@en

Discovery of Potent and Orally ...... Potential Clinical Development

@nl

prefLabel

Discovery of Potent and Orally ...... Potential Clinical Development

@ast

Discovery of Potent and Orally ...... Potential Clinical Development

@en

Discovery of Potent and Orally ...... Potential Clinical Development

@nl

P1433

Q27684218-358672E8-E816-41AD-B791-ACE14B4A243D

P1476

Q27684218-8D0043FC-4FE4-46F7-841A-3CD052954DA1

P2093

Q27684218-06931110-633B-40D0-B005-553D7D1F0B79

Q27684218-14038B4B-CCB4-4DD6-9FCF-7F127C97D12D

Q27684218-14681C8D-672C-4752-9C5B-B1E06C9AF593

Q27684218-4CF45CBC-FF74-4C2D-98CC-D52852857A45

Q27684218-54CE72A4-20EE-44D8-9BD0-71A46D4B820B

Q27684218-5BB23841-86ED-4EC2-A685-D872EBF68A2F

Q27684218-9A7E9AFE-AA3C-4825-8F03-9D00634ABB89

Q27684218-A5BD6842-005F-480B-9C7E-4BA62AE95E28

Q27684218-B7290393-A518-43FC-AA07-F1B1087AF8B1

Q27684218-C0641081-0EB7-4883-913C-92DB0471B584

P2860

Q27684218-01D8D6FC-0DEC-4424-97A5-00FD253A996B

Q27684218-0C9A13A2-42C7-494B-BE4F-056440556907

Q27684218-0CF4076B-CDD6-42D2-A28E-A094D59C808B

Q27684218-14AF25CB-C6C1-4B91-B1BF-CF58FC897DBF

Q27684218-1CD9A58E-AC70-408D-BEBA-097A0ECB5691

Q27684218-2D0D82E3-117A-41AC-B4EE-46FF2D81A2C8

Q27684218-365E7B6A-23D6-4FFD-890D-23585F02E5C0

Q27684218-39DEBB2B-71CD-43AA-9912-B99CD8AB241B

Q27684218-4063B5E3-538B-445C-983D-723F1B3CF2F4

Q27684218-4DF8C2AB-B081-4B90-A7B1-4CB2742E1F09

P304

Q27684218-6A82AABE-F1A7-438B-A057-AE8735A4878C

P31

Q27684218-E53FAAFC-E96C-4D38-8C0D-C1A4A812D197

P3181

Q27684218-EF536F04-F85C-4261-A024-49F7330CEDE5

P356

Q27684218-A38106B0-9254-4108-A574-B739E442737F

P407

Q27684218-707506E6-E610-44A0-8301-8F3B19A662B9

P433

Q27684218-CA0F53E2-9A6E-4D79-AB93-EEB4B41EA0B7

P478

Q27684218-1FEE89E9-A2F8-4447-9C40-BAFE05CD76B5

P577

Q27684218-482CA241-11D3-4F23-92CF-5031D2BEE4CB

P698

Q27684218-1E7585BE-051F-4D17-803F-21B06B12F502

P921

Q27684218-14BDE70E-CF2D-42ED-898D-8ABF9C21A036

Q27684218-AE941BD8-4F02-4809-94DB-38F13178F994

P932

Q27684218-A8CD5255-9C1A-43AE-B4AF-FF3F73EF88B3

P3181

P356

P1433

ACS Medicinal Chemistry Letters

P1476

Discovery of Potent and Orally ...... Potential Clinical Development

@en

P2093

Bradford Graves

http://www.w3.org/2001/XMLSchema#string

Brian Higgins

http://www.w3.org/2001/XMLSchema#string

Christian Tovar

http://www.w3.org/2001/XMLSchema#string

David Bartkovitz

http://www.w3.org/2001/XMLSchema#string

Jin-Jun Liu

http://www.w3.org/2001/XMLSchema#string

Jing Zhang

http://www.w3.org/2001/XMLSchema#string

Kathryn Packman

http://www.w3.org/2001/XMLSchema#string

Kelli Glenn

http://www.w3.org/2001/XMLSchema#string

Lyubomir Vassilev

http://www.w3.org/2001/XMLSchema#string

Nan Jiang

http://www.w3.org/2001/XMLSchema#string

P2860

Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development

p53, the cellular gatekeeper for growth and division

Surfing the p53 network

Functions of the MDM2 oncoprotein

The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation

The p53 pathway: positive and negative feedback loops

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study.

p53 and human cancer: the first ten thousand mutations.

MDM2 is a central node in the p53 pathway: 12 years and counting.

Awakening guardian angels: drugging the p53 pathway.

P304

124-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1358265

http://www.w3.org/2001/XMLSchema#string

P356

10.1021/ML400359Z

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2014-02-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24900784

http://www.w3.org/2001/XMLSchema#string

P921

Aagianik kimischri

P932

4027646

http://www.w3.org/2001/XMLSchema#string